How do weight loss tablets work?
A new type of oral treatment for weight management is arriving in the UK this summer. If you have been hearing about it and want to understand what it actually does and how it is different from older options, this is a plain explanation.
A different kind of tablet
The Wegovy Pill is an oral semaglutide tablet. Semaglutide is a GLP-1 receptor agonist, which means it mimics a hormone your body already produces naturally, called GLP-1 (glucagon-like peptide-1). That hormone is released after you eat and plays several roles: it signals to your pancreas to release insulin, tells your brain you are full and slows the rate at which food moves through your stomach.
In people living with obesity or excess weight, those signals are often weaker or shorter-lived than they need to be. Semaglutide amplifies them.
What that means in practice
When GLP-1 receptors are activated, appetite reduces, often noticeably. Food feels satisfying more quickly. Blood sugar stays more stable after meals. Cravings, particularly for calorie-dense foods, can ease over time.
The result is that eating less becomes easier, not because of willpower, but because the biological signals driving hunger are being addressed directly. That distinction matters. Weight-related challenges are not a character failure. For many people they are, at least in part, a physiological one.
What the tablet does not do on its own
The tablet does not work in isolation. Clinical evidence consistently shows that the best outcomes come when medication is combined with dietary changes, regular movement and sustained support. The medication creates better conditions. What happens within those conditions shapes the result.
That is why CheqUp pairs the Wegovy Pill with ongoing clinical oversight, a dedicated Health Coach and the Weight Watchers app, free with your membership. The tablet is one part of the CheqUp Method, not the whole of it.
How it is different from older oral options
Earlier oral weight loss medications worked through different mechanisms, some carrying significant side effect risks or limited long-term evidence. GLP-1 receptor agonists like semaglutide have a much stronger evidence base. The OASIS 4 Phase 3 trial recorded an average weight loss of approximately 16.6% at the 25mg dose over 64 weeks for participants who followed the full dosing routine. Individual results will vary.
Orlistat is currently the only licensed oral weight loss medicine available in the UK and works by reducing the absorption of dietary fat. It provides 3-5% weight loss in comparison to oral semaglutide, which provides 16.6%.
The Wegovy Pill contains the same active ingredient as the Wegovy injection, in tablet form.
Coming this summer through CheqUp
The Wegovy Pill is not yet available in the UK, but it is coming this summer through CheqUp. If you want to be among the first to know when it is, you can join the waitlist and find out more here.
